317 related articles for article (PubMed ID: 21471286)
1. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
[TBL] [Abstract][Full Text] [Related]
2. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
3. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Haura EB; Sommers E; Song L; Chiappori A; Becker A
J Thorac Oncol; 2010 Nov; 5(11):1806-14. PubMed ID: 20881637
[TBL] [Abstract][Full Text] [Related]
5. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
[TBL] [Abstract][Full Text] [Related]
6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
7. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
8. PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
Petri MK; Brobeil A; Planz J; Bräuninger A; Gattenlöhner S; Nestler U; Stenzinger A; Paradowska A; Wimmer M
J Neurooncol; 2015 May; 123(1):15-25. PubMed ID: 25862004
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
[TBL] [Abstract][Full Text] [Related]
10. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Penne K; Bohlin C; Schneider S; Allen D
Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
13. Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Brown N; McBain C; Nash S; Hopkins K; Sanghera P; Saran F; Phillips M; Dungey F; Clifton-Hadley L; Wanek K; Krell D; Jeffries S; Khan I; Smith P; Mulholland P
PLoS One; 2016; 11(5):e0156369. PubMed ID: 27232884
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
16. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
18. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
19. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Guo D; Prins RM; Dang J; Kuga D; Iwanami A; Soto H; Lin KY; Huang TT; Akhavan D; Hock MB; Zhu S; Kofman AA; Bensinger SJ; Yong WH; Vinters HV; Horvath S; Watson AD; Kuhn JG; Robins HI; Mehta MP; Wen PY; DeAngelis LM; Prados MD; Mellinghoff IK; Cloughesy TF; Mischel PS
Sci Signal; 2009 Dec; 2(101):ra82. PubMed ID: 20009104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
